Historical Valuation
Aura Biosciences Inc (AURA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.44. The fair price of Aura Biosciences Inc (AURA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：5.14
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Aura Biosciences Inc (AURA) has a current Price-to-Book (P/B) ratio of 2.13. Compared to its 3-year average P/B ratio of 2.20 , the current P/B ratio is approximately -2.97% higher. Relative to its 5-year average P/B ratio of 2.40, the current P/B ratio is about -11.34% higher. Aura Biosciences Inc (AURA) has a Forward Free Cash Flow (FCF) yield of approximately -26.38%. Compared to its 3-year average FCF yield of -18.35%, the current FCF yield is approximately 43.74% lower. Relative to its 5-year average FCF yield of -16.10% , the current FCF yield is about 63.83% lower.
P/B
Median3y
2.20
Median5y
2.40
FCF Yield
Median3y
-18.35
Median5y
-16.10
Competitors Valuation Multiple
AI Analysis for AURA
The average P/S ratio for AURA competitors is 0.00, providing a benchmark for relative valuation. Aura Biosciences Inc Corp (AURA.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AURA
1Y
3Y
5Y
Market capitalization of AURA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AURA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AURA currently overvalued or undervalued?
Aura Biosciences Inc (AURA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.44. The fair price of Aura Biosciences Inc (AURA) is between to according to relative valuation methord.
What is Aura Biosciences Inc (AURA) fair value?
AURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aura Biosciences Inc (AURA) is between to according to relative valuation methord.
How does AURA's valuation metrics compare to the industry average?
The average P/S ratio for AURA's competitors is 0.00, providing a benchmark for relative valuation. Aura Biosciences Inc Corp (AURA) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Aura Biosciences Inc (AURA) as of Jan 09 2026?
As of Jan 09 2026, Aura Biosciences Inc (AURA) has a P/B ratio of 2.13. This indicates that the market values AURA at 2.13 times its book value.
What is the current FCF Yield for Aura Biosciences Inc (AURA) as of Jan 09 2026?
As of Jan 09 2026, Aura Biosciences Inc (AURA) has a FCF Yield of -26.38%. This means that for every dollar of Aura Biosciences Inc’s market capitalization, the company generates -26.38 cents in free cash flow.
What is the current Forward P/E ratio for Aura Biosciences Inc (AURA) as of Jan 09 2026?
As of Jan 09 2026, Aura Biosciences Inc (AURA) has a Forward P/E ratio of -3.03. This means the market is willing to pay $-3.03 for every dollar of Aura Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aura Biosciences Inc (AURA) as of Jan 09 2026?
As of Jan 09 2026, Aura Biosciences Inc (AURA) has a Forward P/S ratio of 0.00. This means the market is valuing AURA at $0.00 for every dollar of expected revenue over the next 12 months.